34260-70-3

Basic information

• Product Name: D,L-m-Tyrosine Methyl Ester Hydrochloride
• Synonyms: 2-Amino-3-(3-hydroxyphenyl)propanoic Acid Methyl Ester Hydrochloride;3-Hydroxy-phenylalanine Methyl Ester Hydrochloride;D,L-m-Tyrosine Methyl Ester Hydrochloride
• CAS NO: 34260-70-3
• Molecular Formula: C₁₀H₁₃NO₃*ClH
• Molecular Weight: 0
• Product Categories: Amino Acids 13C, 2H, 15N;Amino Acids & Derivatives;Aromatics
• Mol File: 34260-70-3.mol
• Article Data: 6

Chemical Properties

• Melting Point: 174-176°C
• Appearance: /
• Storage Temp.: Refrigerator
• Solubility: Methanol, Water
• CAS DataBase Reference: D,L-m-Tyrosine Methyl Ester Hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: D,L-m-Tyrosine Methyl Ester Hydrochloride(34260-70-3)
• EPA Substance Registry System: D,L-m-Tyrosine Methyl Ester Hydrochloride(34260-70-3)

Safety Data

• Hazardous Substances Data: 34260-70-3(Hazardous Substances Data)

Usage

Description

D,L-m-Tyrosine Methyl Ester Hydrochloride is a synthetic derivative of the amino acid tyrosine, featuring a methyl ester group and a hydrochloride salt form. D,L-m-Tyrosine Methyl Ester Hydrochloride is characterized by its potential to cross the blood-brain barrier, making it a valuable molecule in pharmaceutical applications.
Used in Pharmaceutical Industry:
D,L-m-Tyrosine Methyl Ester Hydrochloride is used as a therapeutic agent for the treatment of Parkinsonism. It serves as a precursor to the neurotransmitters dopamine and norepinephrine, which are often depleted in individuals with Parkinson's disease. By supplementing with this compound, it can help alleviate symptoms associated with Parkinsonism by increasing the availability of these essential neurotransmitters in the brain.

Upstream product

• 67-56-1 methanol 
• 72683-77-3 N-formyl-L-m-hydroxyphenylalanine 
• 587-33-7 m-tyrosine 
• 775-06-4 D/L-3-hydroxy-phenylalanine 

Downstream Products

• 1031845-64-3 (S)-3-Benzyloxycarbonylamino-N-[(S)-2-(3-hydroxy-phenyl)-1-methoxycarbonyl-ethyl]-succinamic acid benzyl ester 
• 236393-02-5 4-(9H-fluoren-9-ylmethoxycarbonylamino)-4-[2-(3-hydroxy-phenyl)-1-methoxycarbonyl-ethylcarbamoyl]-butyric acid tert-butyl ester 
• 371111-41-0 [S,S]-2-(2-tert-butoxycarbonylamino-2-cyclohexylacetylamino)-3-(3-hydroxyphenyl)propionic acid methyl ester 
• 371111-65-8 10-cyclohexyl-8,11-dioxo-2-oxa-9,12-diazabicyclo[13.3.1]nonadeca-1⁽¹⁹⁾,15,17-triene-13-carboxylic acid 
• 371111-64-7 10-cyclohexyl-8,11-dioxo-2-oxa-9,12-diazabicyclo[13.3.1]nonadeca-1⁽¹⁹⁾,15,17-triene-13-carboxylic acid methyl ester 
• 371111-60-3 methyl 11(S)-cyclohexyl-9,12-dioxo-2-oxa-10,13-diazabicyclo[14.3.1]eicosa-1⁽²⁰⁾,16,18-triene-14(S)-carboxylate 
• 371111-61-4 11(S)-cyclohexyl-9,12-dioxo-2-oxa-10,13-diazabicyclo[14.3.1]eicosa-1⁽²⁰⁾,16,18-triene-14(S)-carboxylic acid 
• 371111-58-9 N-6-heptenoyl-(S)-cyclohexylglycine-(S)-m-tyrosine methyl ester 
• 371111-63-6 2-[2-cyclohexyl-2-(5-hydroxypentanoylamino)acetylamino]-3-(3-hydroxyphenyl)propionic acid methyl ester 
• 371111-59-0 N-7-hydroxyheptanoyl-(S)-cyclohexylglycine-(S)-m-tyrosine methyl ester 
• 371110-98-4 (S)-(2-{3-[((11S,14S)-11-Cyclohexyl-9,12-dioxo-2-oxa-10,13-diaza-bicyclo[14.3.1]icosa-1⁽¹⁹⁾,16⁽²⁰⁾,17-triene-14-carbonyl)-amino]-2-oxo-hexanoylamino}-acetylamino)-phenyl-acetic acid 
• 371111-66-9 (S)-(2-{3-[((10S,13S)-10-Cyclohexyl-8,11-dioxo-2-oxa-9,12-diaza-bicyclo[13.3.1]nonadeca-1⁽¹⁸⁾,15⁽¹⁹⁾,16-triene-13-carbonyl)-amino]-2-hydroxy-hexanoylamino}-acetylamino)-phenyl-acetic acid tert-butyl ester 
• 371110-99-5 (S)-(2-{3-[((10S,13S)-10-Cyclohexyl-8,11-dioxo-2-oxa-9,12-diaza-bicyclo[13.3.1]nonadeca-1⁽¹⁸⁾,15⁽¹⁹⁾,16-triene-13-carbonyl)-amino]-2-oxo-hexanoylamino}-acetylamino)-phenyl-acetic acid tert-butyl ester 
• 371111-62-5 (S)-(2-{3-[((11S,14S)-11-Cyclohexyl-9,12-dioxo-2-oxa-10,13-diaza-bicyclo[14.3.1]icosa-1⁽¹⁹⁾,16⁽²⁰⁾,17-triene-14-carbonyl)-amino]-2-hydroxy-hexanoylamino}-acetylamino)-phenyl-acetic acid tert-butyl ester 

Relevant articles and documents

SMALL MOLECULE MODULATORS OF IL-17

The present invention relates to a compound according to formula I and pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention further relates to, to said compounds for use in therapy, to pharmaceutical compositions comprising said

ANTICANCER AGENTS BASED ON AMINO ACID DERIVATIVES

The present invention provides compounds of formula (I): in which T is L or -A-NH-C(O)-L-; L is -(CH2)n- or -(CH2)p-Z-; A is -(CH2)m- or an alkyl component of a naturally occurring amino acid; R is -CO2R1, -CH2OH, -C(O)NH(hydroxyphenyl) or C(S)NH(hydroxyphenyl); R1 is H or is C1-C12 alkyl; X is -OH, OSO2R2, -Cl, -Br, or -I; R2 is C1-C12 alkyl or -CF3; Z is phenyl or naphthyl; m is an integer having a value of 1 to 20; n is an integer having a value of 1 to 20; and p is an integer having a value of 1 to 20 or an enantiomer, diastereoisomer, racemic mixture, pharmaceutically acceptable salt, solvate or prodrug thereof. These compounds can be useful as anticancer agents.

Synthesis of two novel cyclic biphenyl ether analogs of an inhibitor of HCV NS3 protease

The synthesis of two cyclic ether analogs of a tetrapeptide inhibitor of the hepatitis C virus NS3 protease has been carried out using intramolecular nucleophilic aromatic substitution (S(N)Ar) reactions of ruthenium π-aryl complexes of pre-assembled trip